541 related articles for article (PubMed ID: 24444746)
1. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers.
Yuzwa SA; Cheung AH; Okon M; McIntosh LP; Vocadlo DJ
J Mol Biol; 2014 Apr; 426(8):1736-52. PubMed ID: 24444746
[TBL] [Abstract][Full Text] [Related]
2. Production of O-GlcNAc Modified Recombinant Tau in E. coli and Detection of Ser400 O-GlcNAc Tau In Vivo.
Yuzwa SA; Vocadlo DJ
Methods Mol Biol; 2017; 1523():237-248. PubMed ID: 27975253
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAcylation modulates the self-aggregation ability of the fourth microtubule-binding repeat of tau.
Yu CH; Si T; Wu WH; Hu J; Du JT; Zhao YF; Li YM
Biochem Biophys Res Commun; 2008 Oct; 375(1):59-62. PubMed ID: 18671940
[TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400.
Cameron A; Giacomozzi B; Joyce J; Gray A; Graham D; Ousson S; Neny M; Beher D; Carlson G; O'Moore J; Shearman M; Hering H
FEBS Lett; 2013 Nov; 587(22):3722-8. PubMed ID: 24113653
[TBL] [Abstract][Full Text] [Related]
5. Structural impact of heparin binding to full-length Tau as studied by NMR spectroscopy.
Sibille N; Sillen A; Leroy A; Wieruszeski JM; Mulloy B; Landrieu I; Lippens G
Biochemistry; 2006 Oct; 45(41):12560-72. PubMed ID: 17029411
[TBL] [Abstract][Full Text] [Related]
6. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
Smet-Nocca C; Broncel M; Wieruszeski JM; Tokarski C; Hanoulle X; Leroy A; Landrieu I; Rolando C; Lippens G; Hackenberger CP
Mol Biosyst; 2011 May; 7(5):1420-9. PubMed ID: 21327254
[TBL] [Abstract][Full Text] [Related]
7. Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules.
Fischer D; Mukrasch MD; Biernat J; Bibow S; Blackledge M; Griesinger C; Mandelkow E; Zweckstetter M
Biochemistry; 2009 Oct; 48(42):10047-55. PubMed ID: 19769346
[TBL] [Abstract][Full Text] [Related]
8. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
9. The O-GlcNAc Modification of Recombinant Tau Protein and Characterization of the O-GlcNAc Pattern for Functional Study.
El Hajjar L; Bridot C; Nguyen M; Cantrelle FX; Landrieu I; Smet-Nocca C
Methods Mol Biol; 2024; 2754():237-269. PubMed ID: 38512671
[TBL] [Abstract][Full Text] [Related]
10. Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody.
Yuzwa SA; Yadav AK; Skorobogatko Y; Clark T; Vosseller K; Vocadlo DJ
Amino Acids; 2011 Mar; 40(3):857-68. PubMed ID: 20706749
[TBL] [Abstract][Full Text] [Related]
11. Prediction of human tau 3D structure, and interplay between O-β-GlcNAc and phosphorylation modifications in Alzheimer's disease: C. elegans as a suitable model to study these interactions in vivo.
Ahmad W; Shabbiri K; Ahmad I
Biochem Biophys Res Commun; 2020 Jul; 528(3):466-472. PubMed ID: 32499112
[TBL] [Abstract][Full Text] [Related]
12. β-Sheet core of tau paired helical filaments revealed by solid-state NMR.
Daebel V; Chinnathambi S; Biernat J; Schwalbe M; Habenstein B; Loquet A; Akoury E; Tepper K; Müller H; Baldus M; Griesinger C; Zweckstetter M; Mandelkow E; Vijayan V; Lange A
J Am Chem Soc; 2012 Aug; 134(34):13982-9. PubMed ID: 22862303
[TBL] [Abstract][Full Text] [Related]
13. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments.
Jeganathan S; von Bergen M; Mandelkow EM; Mandelkow E
Biochemistry; 2008 Oct; 47(40):10526-39. PubMed ID: 18783251
[TBL] [Abstract][Full Text] [Related]
14. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS.
Ma Q; Li Y; Du J; Liu H; Kanazawa K; Nemoto T; Nakanishi H; Zhao Y
Peptides; 2006 Apr; 27(4):841-9. PubMed ID: 16225961
[TBL] [Abstract][Full Text] [Related]
15. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
Liu F; Iqbal K; Grundke-Iqbal I; Hart GW; Gong CX
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10804-9. PubMed ID: 15249677
[TBL] [Abstract][Full Text] [Related]
16. Possible role of each repeat structure of the microtubule-binding domain of the tau protein in in vitro aggregation.
Tomoo K; Yao TM; Minoura K; Hiraoka S; Sumida M; Taniguchi T; Ishida T
J Biochem; 2005 Oct; 138(4):413-23. PubMed ID: 16272135
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.
Schneider A; Biernat J; von Bergen M; Mandelkow E; Mandelkow EM
Biochemistry; 1999 Mar; 38(12):3549-58. PubMed ID: 10090741
[TBL] [Abstract][Full Text] [Related]
18. Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules.
González C; Farías G; Maccioni RB
Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1117-27. PubMed ID: 9846894
[TBL] [Abstract][Full Text] [Related]
19. Residual structure in the repeat domain of tau: echoes of microtubule binding and paired helical filament formation.
Eliezer D; Barré P; Kobaslija M; Chan D; Li X; Heend L
Biochemistry; 2005 Jan; 44(3):1026-36. PubMed ID: 15654759
[TBL] [Abstract][Full Text] [Related]
20. Binding of copper (II) ion to an Alzheimer's tau peptide as revealed by MALDI-TOF MS, CD, and NMR.
Ma QF; Li YM; Du JT; Kanazawa K; Nemoto T; Nakanishi H; Zhao YF
Biopolymers; 2005 Oct; 79(2):74-85. PubMed ID: 15986501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
